RVNC•benzinga•
5 Analysts Have This to Say About Revance Therapeutics
Summary
Within the last quarter, Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga